Opposition to Preteen Inoculation Could Pose Challenges to Makers of Experimental HPV Vaccines

Main Category: Sexual Health / STDs
Article Date: 08 Jul 2005 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Pharmaceutical companies GlaxoSmithKline and Merck are competing to get regulatory approval for vaccines that protect against the sexually transmitted disease human papillomavirus -- the leading cause of cervical cancer -- but they also must contend with groups that oppose the widespread vaccination of preteens and children, the... Philadelphia Inquirer reports. Because many people contract the virus the first time they have sexual intercourse, the companies emphasize that the vaccines must be given before sexual debut to be effective (Vrazo, Philadelphia Inquirer, 7/4). Merck -- which makes Gardasil -- said it plans to lobby states to require the vaccine for all 12-year-old children before they can enter school, and GSK -- which manufactures Cervarix -- plans to recommend its HPV vaccine for girls as young as age 10. However, some parents and health officials object to standardized vaccinations for teenagers and are concerned that children would interpret them as permission to have sex (Kaiser Daily Reproductive Health Report, 5/20). "If a 10- or 12-year-old is given a vaccine to protect against sexually transmitted disease, then it's implied they'd be engaging in risky sexual behavior," Pia de Solenni of the Family Research Council said. However, Dayle Steinberg, president of Planned Parenthood of Southeastern Pennsylvania, said it is "ludicrous" to think that teenagers are abstaining from sex because they are concerned about developing cervical cancer later in life. Merck plans to seek FDA approval for Gardasil this year and, if approved, introduce the vaccine in the United States in 2006. GSK plans first to apply for European regulatory approval for Cervarix, which it hopes to receive by 2007, but the company has not announced a timeline for its U.S. application for FDA approval (Philadelphia Inquirer, 7/4). By age 50, 80% of U.S. women have contracted at least one type of HPV (Vollmer, Raleigh News & Observer, 7/3). About 250,000 women worldwide die annually from cervical cancer, and the American Cancer Society estimates that about 3,700 women die of the disease each year in the United States (Kaiser Daily Reproductive Health Report, 5/20).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.



Article adapted by Medical News Today from original press release.
Visit our sexual health / stds section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christian Nordqvist. "Opposition to Preteen Inoculation Could Pose Challenges to Makers of Experimental HPV Vaccines." Medical News Today. MediLexicon, Intl., 8 Jul. 2005. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/27084.php>

APA
Christian Nordqvist. (2005, July 8). "Opposition to Preteen Inoculation Could Pose Challenges to Makers of Experimental HPV Vaccines." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/27084.php.

Please note: If no author information is provided, the source is cited instead.


Sexual Health / STDs

Most Popular Articles



Follow Our Sexual Health News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Sexual Health / STDs Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »